Last reviewed · How we verify
Flublok Quadrivalent influenza vaccine RIV4 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Flublok Quadrivalent influenza vaccine RIV4 (Flublok Quadrivalent influenza vaccine RIV4) — Sanofi Pasteur, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Flublok Quadrivalent influenza vaccine RIV4 TARGET | Flublok Quadrivalent influenza vaccine RIV4 | Sanofi Pasteur, a Sanofi Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Flublok Quadrivalent influenza vaccine RIV4 CI watch — RSS
- Flublok Quadrivalent influenza vaccine RIV4 CI watch — Atom
- Flublok Quadrivalent influenza vaccine RIV4 CI watch — JSON
- Flublok Quadrivalent influenza vaccine RIV4 alone — RSS
Cite this brief
Drug Landscape (2026). Flublok Quadrivalent influenza vaccine RIV4 — Competitive Intelligence Brief. https://druglandscape.com/ci/flublok-quadrivalent-influenza-vaccine-riv4. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab